References

IJMABHR

International Journal of Medical and All Body Health Research

IJMABHR

2582-8940

Anfo Publication House

434

10.54660/IJMBHR.2026.7.1.91-99

Evaluation of Anti-Parkinsons And Monoaminooxidase-B(Mao_B) Inhibitory Properties of Polygonum Cuspidatam In Male Sprague Dawley Rats

Srivani

Meda

Kumari

M Meena

Rani

I Veena

1Student, Department of Pharmacology, SSJ College of Pharmacy, Vattinagulapally, Gandipet, Rangareddy District, India 2Department of Pharmacology, SSJ College of Pharmacy, Vattinagulapally, Gandipet, Rangareddy District, India

14012026

7 1 91 99 05112025 24122025

CC BY-NC-SA 4.0

Background: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by dopaminergic neuronal loss, oxidative stress, and elevated monoamine oxidase-B (MAO-B) activity. Polygonum cuspidatum, rich in antioxidant phytochemicals, has potential neuroprotective effects. Objective: To evaluate the anti-Parkinsonian and MAO-B inhibitory properties of Polygonum cuspidatum ethanolic extract (PCEE) in a 6-hydroxydopamine (6-OHDA) induced rat model of PD. Methods: Rats were divided into five groups: Sham control, 6-OHDA control, 6-OHDA + L-DOPA (6 mg/kg), and 6-OHDA + PCEE (200 and 500 mg/kg). Behavioral assessments (rotarod, catalepsy, and apomorphine-induced rotations) and biochemical analyses (MAO-B activity, dopamine levels via HPLC, lipid peroxidation, catalase, and glutathione levels) were performed. Results: 6-OHDA induced significant motor deficits, elevated MAO-B activity, reduced dopamine, increased lipid peroxidation, and decreased antioxidant enzyme activities. PCEE treatment produced a dose-dependent improvement in motor behavior and significantly inhibited MAO-B activity. Additionally, PCEE restored dopamine levels and antioxidant status, reducing oxidative damage comparable to L-DOPA. Conclusion: Polygonum cuspidatum ethanolic extract exhibits potent anti-Parkinsonian effects through MAO-B inhibition and antioxidant mechanisms, suggesting its potential as a natural therapeutic agent for PD management.

Polygonum CuspidatumL-DOPAOxidative DamageAntioxidant

References 1

Samuelsson G. Drugs of natural origin: a textbook of pharmacognosy. 5th ed. Stockholm: Swedish Pharmaceutical Press; 2004.

Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78(5):431–441.

Khsan MA. Introduction and importance of medicinal plants and herbs. National Health Portal (NHP); 2016.

Walter HL, Memory PF, Elvin L. Medical botany: plants affecting human health. 2nd ed. Hoboken: Wiley; 2003. p. 345.

Patwardhan B, Ashok DB, Chorghade M. Ayurveda and natural products drug discovery. Curr Sci. 2004;86(6):789– 799.

Akerele O. Nature’s medicinal bounty: don’t throw it away. World Health Forum. 1993;14:390–395.

Ballini R, Petrini M. Recent synthetic developments in the nitro to carbonyl conversion. Tetrahedron. 2004;60:1017– 1047.

Henry B, Crossman AR, Jonathan M. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Exp Neurol. 1998;151:334–342.

Mohammad T, Ahmad KH, Moutaery A, Saleh D, et al. Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents. Brain Res Bull. 2001;54:77–82.

Zafar S, Siddiqui A, Sayeed I, Muzamil A, et al. Dose-dependent protective effect of selenium in rat model of Parkinson’s disease: neurobehavioral and neurochemical evidences. J Neurochem. 2003;84:438–446.

Nissinen E. Determination of monoamine oxidase B activity by high-performance liquid chromatography. J Chromatogr Biomed. 1984;309:156–159.

Hefti F, Mohamed E, Liutsuman EJ. Partial lesions of the dopaminergic system in rat brain: biochemical characterization. Brain Res. 1980;195:23–37.

Oiwa Y, Yoshimura R, Nakau K, Itakawa T, et al. Dopaminergic neuroprotection and regeneration by neurotrophin assessed using behavioural, biochemical and histochemical measurements in a model of progressive Parkinson’s disease. Brain Res. 2002;947:27–83.

Brannan T, Prikhojan A, Melvin D. Effects of repeated administration of L-DOPA and apomorphine on circling behavior and striatal dopamine formation. Brain Res. 1998;148–153.

Surendran S, RajaSankar S, Manivasagam T, et al. Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson’s disease model mouse. J Ethnopharmacol. 2009;125:369– 373.

Krishnakumar A, Abraham PM, Paul J, Paulose CS, et al. Down-regulation of cerebellar 5-HT2C receptors in pilocarpine-induced epilepsy in rats: therapeutic role of Bacopa monnieri extract. J Neurol Sci. 2009;284:124–128.

Muzamil A, Seema Y, Badruzzaman KM, Nasrul HM, et al. Attenuation by Nardostachys jatamansi of 6 -hydroxydopamine-induced Parkinsonism in rats: behavioral, neurochemical and immunohistochemical studies. Pharmacol Biochem Behav. 2006;83:150–160.

Kulkarni SK. Practical pharmacology and clinical pharmacy. 1st ed. New Delhi: Vallabh Publications; 2008. p. 156–159.

Zazpe A, Artaiz I, Innerarity A, Olmo ED, et al. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties. Neuropharmacology. 2006;51:129–140.

Del-Bel EA, Souza AS, Guimarães FS, Da-Silva CA, et al. Motor effects of acute and chronic inhibition of nitric oxide synthesis in mice. Psychopharmacology (Berl). 2002;161:32–47.

De Ryck M, Schallert T, Teitelbaum P. Morphine versus haloperidol catalepsy in the rat: a behavioral analysis of postural support mechanisms. Brain Res. 1980;201:143– 172.

Dulley JR, Grieve PA. A simple technique for eliminating interference by detergents in the Lowry method of protein determination. Anal Biochem. 1975;64:136–141.

Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. J Biol Chem. 1949;177:751–766.

Fujikawa T, Miguchi S, Kanada N, Nakai N, et al. Acanthopanax senticosus Harms as a prophylactic for MPTP-induced Parkinson’s disease. J Ethnopharmacol. 2005;97:375–381.